Agios Pharmaceuticals (NASDAQ:AGIO) Stock Rating Upgraded by Zacks Research

Agios Pharmaceuticals (NASDAQ:AGIO) was upgraded by stock analysts at Zacks Research from a “strong sell” rating to a “hold” rating in a research report issued to clients and investors on Tuesday,Zacks.com reports.

A number of other equities analysts also recently commented on the stock. Bank of America reduced their target price on shares of Agios Pharmaceuticals from $52.00 to $51.00 and set a “buy” rating for the company in a report on Tuesday, July 22nd. Scotiabank dropped their price target on Agios Pharmaceuticals from $71.00 to $65.00 and set a “sector outperform” rating on the stock in a research note on Monday, July 28th. HC Wainwright restated a “buy” rating and set a $56.00 price target on shares of Agios Pharmaceuticals in a research note on Thursday, September 4th. Finally, Weiss Ratings restated a “hold (c-)” rating on shares of Agios Pharmaceuticals in a research note on Wednesday, October 8th. Five equities research analysts have rated the stock with a Buy rating and two have issued a Hold rating to the stock. According to MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average target price of $57.25.

Agios Pharmaceuticals Stock Performance

Shares of Agios Pharmaceuticals stock opened at $40.51 on Tuesday. The company has a market capitalization of $2.36 billion, a PE ratio of -5.79 and a beta of 0.89. The company has a 50-day simple moving average of $39.67 and a two-hundred day simple moving average of $36.09. Agios Pharmaceuticals has a one year low of $23.42 and a one year high of $62.58.

Agios Pharmaceuticals (NASDAQ:AGIO) last announced its earnings results on Thursday, October 30th. The biopharmaceutical company reported ($1.78) EPS for the quarter, topping analysts’ consensus estimates of ($1.93) by $0.15. The business had revenue of $12.90 million during the quarter, compared to the consensus estimate of $10.49 million. Agios Pharmaceuticals had a negative net margin of 895.86% and a negative return on equity of 28.35%. The firm’s revenue was up 43.3% on a year-over-year basis. During the same period in the previous year, the company posted $16.22 earnings per share. On average, equities analysts predict that Agios Pharmaceuticals will post -6.85 earnings per share for the current fiscal year.

Insider Buying and Selling

In other news, CFO Cecilia Jones sold 3,651 shares of the stock in a transaction that occurred on Friday, September 26th. The stock was sold at an average price of $36.77, for a total transaction of $134,247.27. Following the transaction, the chief financial officer owned 33,870 shares in the company, valued at $1,245,399.90. This trade represents a 9.73% decrease in their position. The sale was disclosed in a filing with the SEC, which is available at the SEC website. Also, insider Sarah Gheuens sold 3,302 shares of the stock in a transaction that occurred on Monday, October 27th. The shares were sold at an average price of $43.92, for a total value of $145,023.84. Following the transaction, the insider owned 61,727 shares in the company, valued at $2,711,049.84. This trade represents a 5.08% decrease in their position. The disclosure for this sale is available in the SEC filing. In the last quarter, insiders have sold 26,984 shares of company stock worth $1,017,811. 4.30% of the stock is currently owned by company insiders.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently made changes to their positions in the business. Savvy Advisors Inc. purchased a new position in Agios Pharmaceuticals in the 2nd quarter valued at $724,000. Strs Ohio acquired a new stake in shares of Agios Pharmaceuticals in the 1st quarter worth $240,000. American Century Companies Inc. increased its stake in shares of Agios Pharmaceuticals by 9.6% in the 1st quarter. American Century Companies Inc. now owns 114,947 shares of the biopharmaceutical company’s stock worth $3,368,000 after acquiring an additional 10,110 shares during the last quarter. Russell Investments Group Ltd. increased its stake in shares of Agios Pharmaceuticals by 207.6% in the 1st quarter. Russell Investments Group Ltd. now owns 8,558 shares of the biopharmaceutical company’s stock worth $251,000 after acquiring an additional 5,776 shares during the last quarter. Finally, Nordea Investment Management AB increased its stake in shares of Agios Pharmaceuticals by 0.3% in the 2nd quarter. Nordea Investment Management AB now owns 224,746 shares of the biopharmaceutical company’s stock worth $7,520,000 after acquiring an additional 573 shares during the last quarter.

About Agios Pharmaceuticals

Agios Pharmaceuticals, Inc, a biopharmaceutical company, discovers and develops medicines in the field of cellular metabolism in the United States. Its lead product includes PYRUKYND (mitapivat), an activator of wild-type and mutant pyruvate kinase (PK), enzymes for the treatment of hemolytic anemias.